News Focus
News Focus
Followers 59
Posts 7593
Boards Moderated 0
Alias Born 10/20/2014

Re: Monk44 post# 416054

Thursday, 09/28/2023 7:48:12 PM

Thursday, September 28, 2023 7:48:12 PM

Post# of 447735
Monk44, What matters most is if Denner can get BP interested enough to make a reasonable BO offer.
I wish we knew if the version of Vascepa that is absorbed through the Lymphatic system could be viable
as a patentable product. If such a product is more effective in getting into the brain it could become a focus
point for BP to want to acquire AMRN as it could become an Alzheimer's Disease treatment and be a money
maker for BP. Also, such a product may be more effective as an adjunct treatment for various Cancers...Not
a cure, but as a drug that would result in significantly better outcomes than a cancer treatment or drug than
without it. Regardless, only a BP owning AMRN will ever result in optimizing the uptake of the drug as well as
offering protection of the product. (Hard to believe that the idiot CEO JT did not understand that BP had to own
the company in order for the drug to become a success. Even Adam Feuerstein warned him in an article that
he was now playing on Cardiovascular BP turf! JT was "too thick" to understand, and the shareholders along
with CVD patients pay a high price for is idiocy.) Anyhow, I think if "Brave" shows promise the market will
ignore it, but; hopefully, Alex Denner & BP might be paying very close attention.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News